ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.
You may also be interested in...
Gilead Builds Adherence Trial and Behavior Profiling Data Into Truvada PrEP Approval
FDA approval of Gilead’s Truvada for pre-exposure prophylaxis generated national news in advance of the major HIV/AIDS international scientific meeting starting in Washington one week later. As part of the final negotiations to get the approval done in time for the news window, FDA and Gilead worked out an interesting arrangement on post-marketing studies that has broad implications for future sponsors.
Prevnar 13 Advisory Committee Review Moved Back To November
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.
Prevnar 13 Advisory Committee Review Moved Back To November
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.